BRIEF-Edgewise Therapeutics Announces Sale Of Sevasemten For Up To $2.65 Billion, Strengthening Balance Sheet And Centering Company Focus On Cardiovascular Pipeline

Edgewise

Edgewise

EWTX

0.00

June 1 (Reuters) - Edgewise Therapeutics Inc EWTX.O:

  • EDGEWISE THERAPEUTICS ANNOUNCES SALE OF SEVASEMTEN FOR UP TO $2.65 BILLION, STRENGTHENING BALANCE SHEET AND CENTERING COMPANY FOCUS ON CARDIOVASCULAR PIPELINE

  • EDGEWISE THERAPEUTICS - TO RECEIVE $1.55 BILLION UPFRONT AND UP TO $1.1 BILLION IN MILESTONES

  • EDGEWISE THERAPEUTICS - PROCEEDS EXPECTED TO FULLY FUND EDG-7500 DEVELOPMENT THROUGH POTENTIAL APPROVAL

  • EDGEWISE THERAPEUTICS - ON TRACK TO REPORT 12-WEEK CIRRUS-HCM PART D DATA IN Q2 2026

  • EDGEWISE THERAPEUTICS - EMPLOYEES SUPPORTING MUSCULAR DYSTROPHY BUSINESS TO RECEIVE OFFERS FROM SERVIER

Source text: ID:nPn39BCVxa

Further company coverage: EWTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.